Dewpoint Receives FDA Orphan Drug Designation
Dewpoint Therapeutics has received the US FDA's Orphan Drug Designation (ODD) for DPTX3186, a small-molecule condensate modulator for treating gastric cancer.
The ODD program incentivizes the development of medicines for conditions affecting fewer than 200,000 individuals in the US.
- DPTX3186 is a small-molecule condensate modulator for treating gastric cancer.
- The company has opened its investigational new drug application for the oral therapy.
The gold standard of business intelligence.
Dewpoint Therapeutics has entered clinical-stage biotech with the beginning of the first human trial involving a condensate-modulating therapeutic.
Author's summary: Dewpoint receives FDA orphan drug designation.
More News
- The Tech Symphony: AI's Crescendo and the Gadget Orchestra
- Integra stock dips on lowered guidance after Q3 sales miss
- Chipotle’s Stock Plunges 18% On Lowered Guidance
- Best early Black Friday deals 2025: 40+ sales out early
- Eala falls to Mboko to exit Hong Kong Open
- BBMF's Avro Lancaster Begins Major Maintenance Overhaul
- Familial Clustering Identified in Primary Hyperparathyroidism
- Animal Crossing: New Horizons Gets a Free Update and Switch 2 Edition
- Baxter stock slides as Q3 sales come up short, guidance lowered
- Trump Goes Full Dictator With Bonkers Threat to Use Air Force and Navy in U.S. Cities